Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Ray-Coquard

Showing results (21-30 of 548) with videos related to

Pageof 55
Sort By:
Current Opinion in Oncology|May 24, 2023
Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patientsMargherita Turinetto, Pierre Meeus, Isabelle Ray-Coquard
JCO Precision Oncology|January 20, 2022
PARP Inhibitor in Advanced Endometrial Carcinoma Beyond <i>BRCA</i> and Related Genetic MutationsJérôme Alexandre, Isabelle Ray-Coquard, Florence Joly
Lancet (London, England)|January 11, 2026
The Lancet Commission on Ovarian Cancer: towards equity-driven reformIsabelle Ray-Coquard, Chloe Wilson, Kathleen Moore, et al.
Bulletin Du Cancer|September 25, 2013
[Care networks in oncology, an evidence for all?]Isabelle Ray-Coquard, Françoise Ducimetière, Fadila Farsi
Current Opinion in Oncology|June 26, 2021
Importance of guidelines and networking for the management of rare gynecological cancersAlexandra Lainé, Brunhilde Hanvic, Isabelle Ray-Coquard
Current Opinion in Oncology|July 24, 2019
Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?Hélène Vanacker, Clémence Romeo, Isabelle Ray-Coquard
Bulletin Du Cancer|February 9, 2016
[Dualistic classification of epithelial ovarian cancer: Is it clinically relevant?]Mojgan Devouassoux-Shisheboran, Catherine Genestie, Isabelle Ray-Coquard
Bulletin Du Cancer|April 21, 2012
[Iron deficiency and anemia in oncology]Florian Scotté, Vincent Launay-Vacher, Isabelle Ray-Coquard
Bulletin Du Cancer|July 9, 2004
[Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials]Jean-Paul Guastalla, Thomas Bachelot, Isabelle Ray-Coquard
The New England Journal of Medicine|April 16, 2020
PARP Inhibitors in Ovarian Cancer. ReplyIsabelle Ray-Coquard, David Pérol, Eric Pujade-Lauraine
Pageof 55

Showing results (21-30 of 548) with videos related to

Sort By:
Pageof 55
Current Opinion in Oncology|May 24, 2023
Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patientsMargherita Turinetto, Pierre Meeus, Isabelle Ray-Coquard
JCO Precision Oncology|January 20, 2022
PARP Inhibitor in Advanced Endometrial Carcinoma Beyond <i>BRCA</i> and Related Genetic MutationsJérôme Alexandre, Isabelle Ray-Coquard, Florence Joly
Lancet (London, England)|January 11, 2026
The Lancet Commission on Ovarian Cancer: towards equity-driven reformIsabelle Ray-Coquard, Chloe Wilson, Kathleen Moore, et al.
Bulletin Du Cancer|September 25, 2013
[Care networks in oncology, an evidence for all?]Isabelle Ray-Coquard, Françoise Ducimetière, Fadila Farsi
Current Opinion in Oncology|June 26, 2021
Importance of guidelines and networking for the management of rare gynecological cancersAlexandra Lainé, Brunhilde Hanvic, Isabelle Ray-Coquard
Current Opinion in Oncology|July 24, 2019
Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?Hélène Vanacker, Clémence Romeo, Isabelle Ray-Coquard
Bulletin Du Cancer|February 9, 2016
[Dualistic classification of epithelial ovarian cancer: Is it clinically relevant?]Mojgan Devouassoux-Shisheboran, Catherine Genestie, Isabelle Ray-Coquard
Bulletin Du Cancer|April 21, 2012
[Iron deficiency and anemia in oncology]Florian Scotté, Vincent Launay-Vacher, Isabelle Ray-Coquard
Bulletin Du Cancer|July 9, 2004
[Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials]Jean-Paul Guastalla, Thomas Bachelot, Isabelle Ray-Coquard
The New England Journal of Medicine|April 16, 2020
PARP Inhibitors in Ovarian Cancer. ReplyIsabelle Ray-Coquard, David Pérol, Eric Pujade-Lauraine
Pageof 55